Protalix BioTherapeutics (PLX) Reports Q1 Loss of $0.48/Shre

Protalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of ($0.48), versus ($0.09) reported last year. Revenue for the quarter came in at $2.9 million versus the consensus estimate of $679 thousand.

• Positive Results from Phase II Trial in CF Program with Number of Potential Strategic Alternatives for Further Development
• First Ever Once Monthly Dosing Trial in Fabry Patients to Commence Next Quarter
• Continued Progress in the Commercialization of alfataliglicerase in Brazil

For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.

You May Also Be Interested In

• Norwegian Cruise Line Holdings (NYSE: NCLH) PT Raised to $20 at UBS
• Prenetics IM8 revenue jumps 359% in Q2, raises FY2026 guidance
• Evogene (EVGN) Tops Q2 EPS by 15c